AR and triple-negative breast carcinoma: Although several groups use endogenously AR-expressing MDA-MB-453 cells to evaluate androgen actions in triple negative breast cancers, MDA-MB-453 cells have AR, PTEN, and PIK3CA oncogenic mutations, HER2 over-expression and are p53 null [8].